SARS-CoV-2 Spike receptor binding domain, RBD (336-347) – 0.5 mg

Overview

The SARS-CoV-2 Spike receptor binding domain (RBD) peptide, specifically the sequence covering residues 336-347, is a crucial component in SARS-CoV-2 research. This peptide is derived from the spike protein of the virus, which plays a significant role in its ability to bind to human cells. Understanding this domain is essential for the development of vaccines and therapeutic agents aimed at combating COVID-19.

Key Features

• Consists of residues 336-347 from SARS-CoV-2 RBD.
• Identified from the RefSeq sequence YP_009724390.1.
• Supports research in vaccine development and therapeutic interventions.
• Available in a convenient 0.5 mg size suitable for various applications.
• High purity grade ensures reliable and reproducible results in experiments.

Specifications

FAQ

What is the role of the RBD in SARS-CoV-2?

The receptor binding domain (RBD) of the spike protein is critical for the virus’s ability to attach to ACE2 receptors on human cells, facilitating infection.

How can I use this peptide in my research?

This peptide can be used for various applications, including binding studies, antibody assays, and protein interaction experiments. For related products, check out our PKG substrate and the Autocamtide-2 peptide.

Is this peptide suitable for therapeutic use?

While this peptide is primarily intended for research purposes, its understanding can contribute to developing therapeutic strategies and vaccines against COVID-19.

If you’re looking to buy high-quality peptides for your research, this SARS-CoV-2 Spike RBD peptide is an excellent choice. Ensure you stay ahead in your studies with our specialized products.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled

Browse more in Peptides.